WO1998006383A1 - Homeopathic composition and process for its preparation - Google Patents
Homeopathic composition and process for its preparation Download PDFInfo
- Publication number
- WO1998006383A1 WO1998006383A1 PCT/GB1997/002124 GB9702124W WO9806383A1 WO 1998006383 A1 WO1998006383 A1 WO 1998006383A1 GB 9702124 W GB9702124 W GB 9702124W WO 9806383 A1 WO9806383 A1 WO 9806383A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- radiation
- homeopathic
- process according
- preparation
- dilution step
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
Definitions
- This invention relates to a process for the production of a homeopathic medicinal composition, the product of such a process, and a package containing such a product.
- Homeopathic medicine is a system of healing which has been in existence since 1796.
- the word homeopathy comes from the Greek language and may be translated as "similar suffering” .
- an agent which can cause disease in a healthy person can be used to therapeutic advantage in a person who is sick and whose symptoms resemble those of the agent.
- the agent is administered to a patient in minute amount and in very high dilution, in contrast to the practice in allopathic medicine in which the therapeutic agent is normally administered to a patient in much higher amount and at a much higher concentration.
- the agent can be administered in the form of a solution, as an ointment or paste, as tablets, or in the form of pellets or globules of a carrier, such as lactose, which has been impregnated with a dilute solution of the agent. Alternatively it is possible to triturate the agent with a solid carrier.
- a typical size for pellets is around 200 per gram, while globules typically come in a size of about 20 per gram. Tablets may be of any suitable size which are convenient for swallowing, for example about 0.2 g to about 1 g.
- the resulting diluted mixture has a Hahnemannian Concentration which, for convenience, can be designated 1 CH.
- 1% by volume of this 1 CH solution is again mixed with 99% by volume of diluent.
- the resulting diluted solution can be designated 2 CH.
- the Korsakovian process is undertaken in a single bottle or flask. In this case 99% of a starting solution (or mother tincture) is drained or aspirated from the bottle or flask and the remaining 1% by volume is diluted by pouring in 99% by volume of the diluent. After mixing the resulting solution can, for convenience, be designated the first Korsakovian centesimal (or 1 cmK) . Upon repeating the procedure with the 1 cmK solution a further diluted solution, i.e. the 2 cmK solution, is obtained. By carrying out the procedure N times the Nth cmK solution can be obtained.
- the number of operations that require to be carried out in order to reach a desired level of dilution can be summarised as shown in Table 1 below.
- the starting concentration is a convenient concentration, such as 1 g per litre .
- Hahnemann recommended that utensils used for the preparation of a homeopathic medicinal preparation should be sterilised in boiling water. He also recommended that, in order to have a correct succussion effect in diluting a solution, the bottle should be large enough to be only two thirds filled up. In order to develop the dynamic pharmaceutical virtues of the preparations, the bottle should be submitted to a series of strong succussions. Typically this should involve pounding the bottle filled to 75% or 50% with the solution on a thick book having a leather cover 100 times at the frequency of the heart's beat. Furthermore the prepared solutions should be stored and protected from the sun and the daylight in a well sealed bottle.
- homeopathic preparations produced by the dilution methods of Hahnemann and Korsakoff can produce effective homeopathic medicinal preparations, their effectiveness is variable. It would accordingly be desirable to provide a process for preparing homeopathic medicinal preparations which can enable the reliable production, preferably on an industrial scale, of homeopathic medicinal preparations with reproducible effects. It would further be desirable to provide a homeopathic medicinal product in a form which, it can be ensured, will reach the patient in optimal condition and with its efficacy undiminished.
- the compound having homeopathic efficacy may be any agent conventionally used in homeopathic medicine.
- the diluent generally comprises a solvent, such as water, ethyl alcohol, or a mixture thereof.
- the diluent preferably comprises water.
- the dilution step (b) is repeated a plurality of times including a final dilution step and in the final dilution step the diluent is a solid.
- the diluent is preferably a solvent.
- the final dilution step comprises impregnating granules or globules of a solid carrier material with a solution of the agent.
- a typical solid carrier material comprises a carbohydrate, such as a saccharose, for example lactose, sucrose, threalose, threose, or the like. A mixture of saccharoses can be used.
- the solid carrier material may, for example, comprise particles weighing from about 0.005 g to about 0.05 g.
- the solid carrier can alternatively be formed into tablets weighing, for example, from about 0.2 g up to about 1 g or more, e.g. up to about 2 g.
- the final dilution step may alternatively comprise formulation as an ointment or paste using a conventional excipient or excipients.
- the shielding step is effected so as to shield from ⁇ ⁇ radiation, including emitted ⁇ - radiation in the tritium energy range.
- the shielding should be effective to prevent penetration of - particles.
- these operations can be carried out inside a Faraday cage. Normally such shielding will also be effective to prevent penetration by ⁇ particles; it is, however, impractical to attempt to provide shielding against ⁇ rays.
- the shielding step is preferably carried so as to shield from ⁇ radiation having energy in the range of up to about 19 keV.
- the shielding step can be carried out so as to shield from ⁇ " radiation energy in the range of from about 1 keV to about 19 keV.
- the packaging step includes packaging the homeopathic medicinal preparation in a container substantially impervious to ⁇ " radiation, including emitted ⁇ - radiation in the tritium energy range.
- a container may comprise a composite container comprising an inert inner container and an outer shield substantially impervious to ⁇ " radiation, including emitted ⁇ - radiation in the tritium energy range.
- the storage container may, for example, comprise a metal selected from aluminium, nickel and copper.
- the dilution step (b) preferably includes a succussion step.
- Succussion can be imparted manually; in this case the succussion should preferably be carried using a gloved hand so as not to supply heat to the flask or other container during succussion.
- the flask or other container can be succussed mechanically. It is desirable to avoid stirring the solution during succussion in such a way as to produce a vortex.
- a suitable succussion regimen involves shaking the flask or other container mechanically at a frequency in the range of from about 0.1 Hz to about 60 Hz with an amplitude of about 40 mm for a period of about 10 seconds. Whilst succussion is desirable, it should not be so vigorous as to impart energy to the solution of more than about 85000 kJ/mole.
- the invention provides a homeopathic medicinal preparation which has been prepared according to the process of the invention.
- the invention further provides a storage container which is adapted to shield its contents from the effects of ⁇ " radiation, including emitted ⁇ ⁇ radiation in the tritium energy range, containing a charge of a homeopathic medicinal preparation containing an agent having homeopathic efficacy, which preparation has been prepared by a process which comprises :
- the storage container is adapted to contain a unit dosage of the homeopathic medicinal composition, for example about 1 g of granules or globules, one or more tablets, or a suitable amount of a liquid, an ointment or paste.
- Such a container can be a screw capped container, a container with a childproof cap, a container with a slide-off cap, a sealed ampoule with a frangible tip, or a bag made of a metallised plastics material.
- the container may be provided with a tamperproof seal of conventional design so as to indicate to the patient that the homeopathic medicinal preparation contained therein has remained shielded from ⁇ ⁇ radiation, including emitted ⁇ * radiation in the tritium energy range, since packaging was effected.
- the conventional dilution methods of Hahnemann or of Korsakoff can be used in which the initial solution, which is of any convenient strength, is diluted by a factor of one hundred or ten at each dilution stage.
- the initial solution can be diluted by a method (which we have termed the GCL method) which involves dilution in a first dilution step by a factor of 100 and mixing by succussion.
- the flask should be shaken a number of times in the same direction, e.g. horizontally or vertically, in order to introduce into the diluted solution energy in the range of, for example, from about 10 "3 to about 200 J/g .
- This solution can be termed a 1 G solution.
- the succussed diluted solution resulting from such a first dilution step is diluted by discarding one fifth of its volume and replacing the discarded volume with further diluent and again succussing the resulting solution.
- This resulting solution can be termed a 2 G solution.
- the concentrations in the resulting solution are set out in Table 2 below. TABLE 2
- a molar solution of a substance contains, according to accepted molecular theory, 6.023 x 10 23 molecules (i.e.
- Figure 1 is a diagram of an experimental apparatus used in Example 1 ;
- Figure 2 is a diagram illustrating the inhomogeneous spread of mass in the space-time continuum. The invention is illustrated by the following Examples. E ample i
- a PyrexTM vessel 1 which was 10 cm in diameter was filled to a depth of approximately 8 cm with 500 ml of de-ionised water 2.
- a tube 3 which was 18 cm in length was filled to a depth of about 3.5 cm with 2 ml of a D 5 thyroxine solution 4 produced by dilution and succussion.
- This tube 3 was placed in the flask 1. In this way the ratio of the volume of water 2 in the flask 1 to the volume of solution 4 was 500:2 or 250:1.
- the flask 1 and tube 3 was protected from direct or indirect sunlight and from any extraneous source of ultraviolet radiation.
- the tube 3 was placed directly in the water 2. In a second series of experiments the tube 3 was wrapped with aluminium foil 13 ⁇ m thick before being placed in the water 2.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BR9711051-5A BR9711051A (en) | 1996-08-09 | 1997-08-05 | Process, product and packaging. |
JP10509484A JP2000516605A (en) | 1996-08-09 | 1997-08-05 | Homeopathic composition and its preparation process |
AU37046/97A AU714261B2 (en) | 1996-08-09 | 1997-08-05 | Homeopathic composition and process for its preparation |
NZ334086A NZ334086A (en) | 1996-08-09 | 1997-08-05 | A process for preparing plurality of homeopathic compositions |
EP97933810A EP0918512A1 (en) | 1996-08-09 | 1997-08-05 | Homeopathic composition and process for its preparation |
CA002263097A CA2263097A1 (en) | 1996-08-09 | 1997-08-05 | Homeopathic composition and process for its preparation |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9616728.3 | 1996-08-09 | ||
GBGB9616728.3A GB9616728D0 (en) | 1996-08-09 | 1996-08-09 | Process, product and package |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998006383A1 true WO1998006383A1 (en) | 1998-02-19 |
Family
ID=10798244
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB1997/002124 WO1998006383A1 (en) | 1996-08-09 | 1997-08-05 | Homeopathic composition and process for its preparation |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP0918512A1 (en) |
JP (1) | JP2000516605A (en) |
AU (1) | AU714261B2 (en) |
BR (1) | BR9711051A (en) |
CA (1) | CA2263097A1 (en) |
GB (1) | GB9616728D0 (en) |
NZ (1) | NZ334086A (en) |
WO (1) | WO1998006383A1 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0943325A1 (en) * | 1998-03-18 | 1999-09-22 | Gerhard Moser | Process for making homeopathic medicaments |
FR2793657A1 (en) * | 1999-05-19 | 2000-11-24 | Sante Nutrition Selection Diff | Micronutritional products, useful as general tonic or for skin treatment, comprises oligo-element, plant, food principle and vitamin components, prepared by specific mixing method to potentiate activity |
WO2003019316A1 (en) * | 2001-08-22 | 2003-03-06 | Reyes Arellano J Cristobal | Homeopathic stimulant composition for seed production |
FR2883654A1 (en) * | 2005-03-25 | 2006-09-29 | Jean Francois Comet | Homeopathic drug fabricating succussion number and quality counting device for community pharmacy field, has case with counter having four digits, where two digits out of four digits count number of succussions of dilution in progress |
US20160354302A1 (en) * | 2014-01-07 | 2016-12-08 | Deborah Mitchell | Methods involving skin cosmetics |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113347995A (en) * | 2018-12-28 | 2021-09-03 | 卢遂显 | Preparation method of solid water particles for homeopathy |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4765379A (en) * | 1987-07-03 | 1988-08-23 | Laboratoires De Pharmacologie Homeopathique Dolisos - Laboratoires Jean Tetau | Plug and outer cap for closing a container |
CH670766A5 (en) * | 1986-04-12 | 1989-07-14 | Helmut Dr Dr Med Fichter | Earth radiation elimination device for homeopathic treatment - has respective coils contained in successive compartments along length of wooden housing |
WO1991015197A1 (en) * | 1990-04-07 | 1991-10-17 | Beecham Group Plc | Pharmaceutical formulation |
US5401502A (en) * | 1992-01-17 | 1995-03-28 | Alfatec Pharma Gmbh | Pellets containing plant extracts, process of making same and their pharmaceutical peroral or cosmetic use |
-
1996
- 1996-08-09 GB GBGB9616728.3A patent/GB9616728D0/en active Pending
-
1997
- 1997-08-05 NZ NZ334086A patent/NZ334086A/en unknown
- 1997-08-05 BR BR9711051-5A patent/BR9711051A/en not_active IP Right Cessation
- 1997-08-05 AU AU37046/97A patent/AU714261B2/en not_active Ceased
- 1997-08-05 CA CA002263097A patent/CA2263097A1/en not_active Abandoned
- 1997-08-05 WO PCT/GB1997/002124 patent/WO1998006383A1/en not_active Application Discontinuation
- 1997-08-05 EP EP97933810A patent/EP0918512A1/en not_active Withdrawn
- 1997-08-05 JP JP10509484A patent/JP2000516605A/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH670766A5 (en) * | 1986-04-12 | 1989-07-14 | Helmut Dr Dr Med Fichter | Earth radiation elimination device for homeopathic treatment - has respective coils contained in successive compartments along length of wooden housing |
US4765379A (en) * | 1987-07-03 | 1988-08-23 | Laboratoires De Pharmacologie Homeopathique Dolisos - Laboratoires Jean Tetau | Plug and outer cap for closing a container |
WO1991015197A1 (en) * | 1990-04-07 | 1991-10-17 | Beecham Group Plc | Pharmaceutical formulation |
US5401502A (en) * | 1992-01-17 | 1995-03-28 | Alfatec Pharma Gmbh | Pellets containing plant extracts, process of making same and their pharmaceutical peroral or cosmetic use |
Non-Patent Citations (1)
Title |
---|
NEGTIEN, G. ET AL.: "Notions Pratiques de Pharmacie Homeopathique", 1986, TECHNIQUE ET DOCUMENTATION, PARIS,FR, XP002047534, 16 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0943325A1 (en) * | 1998-03-18 | 1999-09-22 | Gerhard Moser | Process for making homeopathic medicaments |
FR2793657A1 (en) * | 1999-05-19 | 2000-11-24 | Sante Nutrition Selection Diff | Micronutritional products, useful as general tonic or for skin treatment, comprises oligo-element, plant, food principle and vitamin components, prepared by specific mixing method to potentiate activity |
WO2000070968A1 (en) * | 1999-05-19 | 2000-11-30 | Sante Nutrition Selection Diffusion S.A.R.L. | Method for making products used in sequential micronutrition and uses of resulting products |
WO2003019316A1 (en) * | 2001-08-22 | 2003-03-06 | Reyes Arellano J Cristobal | Homeopathic stimulant composition for seed production |
FR2883654A1 (en) * | 2005-03-25 | 2006-09-29 | Jean Francois Comet | Homeopathic drug fabricating succussion number and quality counting device for community pharmacy field, has case with counter having four digits, where two digits out of four digits count number of succussions of dilution in progress |
US20160354302A1 (en) * | 2014-01-07 | 2016-12-08 | Deborah Mitchell | Methods involving skin cosmetics |
Also Published As
Publication number | Publication date |
---|---|
JP2000516605A (en) | 2000-12-12 |
BR9711051A (en) | 2000-01-11 |
CA2263097A1 (en) | 1998-02-19 |
GB9616728D0 (en) | 1996-09-25 |
AU714261B2 (en) | 1999-12-23 |
EP0918512A1 (en) | 1999-06-02 |
NZ334086A (en) | 2000-05-26 |
AU3704697A (en) | 1998-03-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU714261B2 (en) | Homeopathic composition and process for its preparation | |
EP1379297A1 (en) | Process and device for preparing radiopharmaceutical products for injection | |
DE2545973B2 (en) | Process for the preparation of a digoxin medicament in the form of therapeutic unit doses | |
CN102133225B (en) | Compound polyethylene glycol electrolyte pulvis and preparation method thereof | |
CN1211175A (en) | Medicament and method of treating an organism with medicaments | |
RU2161955C1 (en) | Method of varying physico-chemical and biological properties of substance | |
AU727171B2 (en) | Process to produce solid homeopathic compositions | |
US3297529A (en) | Magnesium sulfate stabilized choline salicylate | |
Xiao-fei et al. | Preliminary study: biotransformation of borneol to camphor in mice, rats, and rabbits | |
JPH07503468A (en) | Sodium iodide ↑1↑3↑11 capsules | |
Dugani et al. | Effects of the aqueous extract from Abelmoschus esculentus L peel on hyperglycemia and hyperlipidemia induced by dexamethasone in rats | |
US3787565A (en) | Method of producing a diagnostic preparation on the basis of an iron complex labelled with 99m tc | |
Karunanithy et al. | Undeclared drugs in traditional Chinese antirheumatoid medicine | |
US4775533A (en) | Reconstitution of dry fill cyclophosphamide | |
Moreira et al. | Elemental composition of herbal medicines sold over-the-counter in Sao Paulo city, Brazil | |
Bajaj et al. | Determination of alcoholic content of Asava and Arishta by distillation method and specific gravity method | |
Dougall et al. | Paracetamol absorption from Paramax, Panadol and Solpadeine. | |
Leal et al. | Quality Control of Formulated Medicines | |
Newton et al. | The in vitro bioavailability of various drugs formulated as hard gelatin capsules | |
EP1032832A1 (en) | Methods and apparatus for determining beta radiation spectra | |
Bezpala et al. | Development of the gel technology for treating inflammatory diseases of the oral mucosa | |
CN112618589A (en) | Traditional Chinese medicine health-care medicine formula and preparation method thereof | |
CN112915066A (en) | Glabrous sarcandra herb formula granules and preparation method thereof | |
CN112675213A (en) | Traditional Chinese medicine composition, preparation method, preparation and application thereof | |
JP2000516508A (en) | Storage and display units |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2263097 Country of ref document: CA Ref country code: CA Ref document number: 2263097 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 334086 Country of ref document: NZ |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 1998 509484 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1997933810 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09242212 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1997933810 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1997933810 Country of ref document: EP |